Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5852 - Tolerance and efficacy of immune-checkpoint inhibitors for cancer in people living with HIV (PWHIV)

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Aurélien Gobert

Authors

A. Gobert1, M. Veyri2, A. Lavolé3, H. Montaudié4, N. Cloarec5, L. Doucet6, V. Gounant7, M. Massiani8, C. Helissey9, S. Bregigeon10, C. Chouaid11, C. Poulet12, M. Dewolf13, M. Kerjouan14, S. Beaucaire-Danel15, S. Brosseau16, G. Le Garff17, V. Garrait18, A. Marcelin19, J. Spano1

Author affiliations

  • 1 Medical Oncology, Groupe Hospitalier Pitié-Salpêtrière, 75651 - Paris/FR
  • 2 Medical Oncology, Groupe Hospitalier Pitié-Salpêtrière, 75013 - Paris/FR
  • 3 Pneumology, Hospital Tenon, APHP, 75020 - Paris/FR
  • 4 Department Of Dermatology, Nice university hospital, INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, Team 12, Nice/FR
  • 5 Hematology And Medical Oncology, CH Avignon, Avignon/FR
  • 6 Medical Oncology, Hôpital St. Louis, 75010 - Paris/FR
  • 7 Pneumology, Hopital Bichat Claude Bernard, 75018 - Paris/FR
  • 8 Medical Oncology, Institut Curie, Saint-Cloud/FR
  • 9 Val De Marne, Bégin Military Teaching Hospital, 94160 - Saint-Mandé/FR
  • 10 Clinical Immunology And Hematology Center, AP-HM, Marseille/FR
  • 11 Chest Department, Centre Hospitalier Intercommunal Créteil, Créteil/FR
  • 12 Pneumology, CHU Amiens-Picardie Site Sud, 80054 - Amiens/FR
  • 13 Pneumology, CHU Reims, Reims/FR
  • 14 Pneumology, CHU Rennes, Rennes/FR
  • 15 Department Of Oncology, Institut Curie, 75248 cedex5 - Paris/FR
  • 16 Pneumlogy, Hopital Bichat Claude Bernard, 75018 - Paris/FR
  • 17 Pneumology, CH Saint Brieuc, Saint Brieuc/FR
  • 18 Tropical And Infectious Disease Department, CHIC Créteil, Créteil/FR
  • 19 Virology, groupe Hospitalier Pitié Salpetriere, Paris/FR
More

Resources

Abstract 5852

Background

Immunotherapy with anti-PD-1/PD-L1 inhibitors represents a breakthrough in cancer treatment. Because PWHIV are usually excluded from clinical trials, tolerance and efficacy data are limited in this population. The French national network CANCERVIH is dedicated to the management of cancer in PWHIV with the organization of the national multidisciplinary meetings ONCOVIH. The objective of this study was to evaluate tolerance and efficacy of nivolumab, an anti-PD-1 inhibitors, in this specific population.

Methods

This study was conducted using the CANCERVIH database. Patients presented in national multidisciplinary meetings since May 2014 were evaluated. Demographic, CD4 lymphocyte count, HIV viral load, tolerance and efficacy data were retrospectively collected from patients treated with nivolumab in daily practice.

Results

Since May 2014, 470 patients have been presented in ONCOVIH national multidisciplinary meetings. Immunotherapy has been proposed for 35 patients and 20 were treated in current practice: 19 (95%) for metastatic non small-cell lung cancer and 1 (5%) for metastatic melanoma. The median CD4 lymphocyte count at diagnosis was 338,5/mm3 (241,3 – 490,5). HIV viral load was undetectable in 17 patients, less than 40 copies/mL in 2 patients and unknown in 1 patient. At the cut-off analysis, with a median follow-up of 10,8 months (1,0 – 27,7), the median number of injections was 6 (3 – 53). No toxic deaths or immune related adverse events have been noted. Only one patient experienced a rising HIV viral load and a decreasing CD4 lymphocyte count but after antiretroviral therapy interruption. On the 17 patients evaluable for response, 4 (24%) had partial response, 2 (12%) had stability and 11 (64%) had disease progression at first evaluation.

Conclusions

Based on these preliminary data, treatment with anti-PD-1 inhibitors seems to be feasible in PWHIV. Antiretroviral therapy should not be interrupted. CD4 lymphocyte count and HIV viral load should be monitored during treatment with immune-checkpoint inhibitors and patients should be included in dedicated clinical trials. Data will be updated at the meeting presentation to better determine tolerance and efficacy of anti-PD-1 inhibitors in this population.

Clinical trial identification

Editorial Acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings